Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseobservationalRules rewrite
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osi…
A prospective ,multicenter ,non-treatment ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 950 people at Beijing. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers After Three Weeks of Osimertinib Targeted Therapy in Chinese Patients With Stage IIIB ,IIIC ,or IV Metastatic or Recurrent Non Squamous EGFR-positive Non-small Cell Lung Cancer
Primary outcome (registry wording): To describe the characteristics of EGFR mutation changes at baseline and after 3 weeks of osimertinib treatment
Who it is for (from inclusion criteria)
Ages 18 Years to any
Male or female,age ≥18 years
Newly diagnosed,histologically confirmed,and classified as stage IIIB,IIIC,IV or recurrent NSCLC which are not amenable to curative surgery or radiotherapy
No prior systemic antitumor therapy, including EGFR -TKIs or immunotherapy
Presence of an EGFR mutation confirmed by a local laboratory in blood or tissue samples
Adequate blood samples available for molecular testing
Who the registry excludes
Inability to provide plasma samples at baseline
Baseline blood EGFR mutation status not confirmed by the central laboratory
Refusal to receive subsequent treatment with osimertinib
Any condition that ,in the investigator's judgment ,could interfere with study procedures or confound outcome assessment
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
1 listed
Cancer Hospital Chinese — Beijing, China (recruiting)
Related recruiting trials in this snapshot
RecruitingNot a traditional drug phaseBethesda, Maryland
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols.
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06422546?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06422546?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.